The product will be manufactured at the company's Bengaluru facility and marketed by Strides Pharma Inc in the US market.
In a BSE filing, Strides Shasun said it has received approval from the United States Food and Drug Administration (USFDA) for promethazine hydrochloride tablets USP, 12.5mg, 25 mg and and 50 mg.
Citing IMS sales data, Strides Shasun said the US market for the approved product is approximately $17 million.
The stock was trading 0.86 per cent higher at Rs 1,007 on the BSE.
(This story has not been edited by NDTV staff and is auto-generated from a syndicated feed.)